Innovative Cell-Based Therapy Shows Promise for Ovarian Cancer Treatment

First-in-Human Trial of Encapsulated Cytokine Factories for Ovarian Cancer

Recent advancements in immunotherapy have led to the development of implantable cytokine factories, which deliver therapeutic proteins directly to the tumor site. A significant clinical milestone has been achieved through a first-in-human trial at Rice University, in partnership with The University of Texas MD Anderson Cancer Center. This innovative approach addresses advanced ovarian cancer, specifically high-grade serous ovarian carcinoma, by utilizing a localized delivery method for interleukin-2 (IL-2).

The trial, detailed in the publication Clinical Cancer Research, evaluated a novel treatment known as AVB-001. This investigational therapy relies on encapsulated cells capable of producing IL-2 within the abdominal cavity. Unlike traditional IL-2 therapy, which faces challenges such as severe side effects and short drug efficacy, this method not only aims to improve efficacy but also reduce toxicity.

Omid Veiseh, a professor of bioengineering at Rice, emphasized the benefits of this localized delivery format: “Traditional IL-2 therapy has demonstrated substantial antitumor effects, but its use has often been curtailed due to adverse side effects. Our new platform enables us to administer the cytokine exactly where it's needed, minimizing systemic exposure and related risks.”

In this Phase I trial, 14 patients with platinum-resistant ovarian cancer underwent a single treatment using AVB-001, administered through a minimally invasive laparoscopic procedure. Remarkably, the treatment was well-tolerated, with no life-threatening adverse events reported, and participants did not reach a maximum tolerated dose. Encouragingly, 50% of participants demonstrated disease stabilization, with some experiencing prolonged clinical benefit. Dr. Shannon Westin from MD Anderson stated, “For patients with limited options, achieving stability is a notable success.”

Furthermore, immune analyses revealed that AVB-001 activated crucial antitumor immune components, including CD8+ T cells and natural killer cells, while avoiding the expansion of regulatory T cells that commonly suppress immune activity in conventional therapies. Noteworthy increases in inflammatory cytokines confirmed the therapy’s effective mechanism.

An important finding of the study was the dose-dependent increase in CTLA-4, an immune checkpoint protein, suggesting that combining AVB-001 with checkpoint inhibitors could enhance overall antitumor responses.

“What’s groundbreaking is that we’re not simply administering a drug; we’re engineering a supportive microenvironment for immune functions,” remarked Dr. Amir Jazaeri at MD Anderson. This concept might facilitate combination treatments that can activate immune responses more effectively than current methodologies.

The implants’ design allows for the sustained release of IL-2 over approximately a week, with the potential for repeating doses to achieve better therapeutic results. Preclinical studies in nonhuman primates showed that repeat doses were well tolerated and engaged consistent pharmacological effects without additional toxicity.

“This represents a foundational advancement in our research,” added Veiseh, who is also the director of the Rice Biotech Launch Pad. “The evidence of safety and biological activity supports the scaling of this therapy. We will focus on optimizing dosing and potential combination therapies to maximize its clinical efficacy.”

The promising outcomes from this trial reflect the collaborative efforts within the Houston biotechnology network. Ongoing and future studies will likely explore higher doses, repeated administrations, and combinations with checkpoint inhibitors, paving the way for enhanced therapeutic options for ovarian cancer patients.

This research is funded by the Advanced Research Projects Agency for Health (ARPA-H), underlining the potential impact of innovative biotech solutions in oncology. The trial results underline the significant strides made towards redefining treatment protocols for ovarian cancer, possibly offering hope to many who have limited options at present.